Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Announces Earnings Results

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) issued its quarterly earnings results on Monday. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.06, FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Stock Down 1.3%

Shares of Damora Therapeutics, Inc. Common Stock stock opened at $29.54 on Tuesday. The company has a market cap of $1.82 billion, a PE ratio of -5.29 and a beta of 1.47. Damora Therapeutics, Inc. Common Stock has a 52 week low of $2.45 and a 52 week high of $38.33. The business has a 50 day moving average price of $26.55 and a 200-day moving average price of $26.29.

Analyst Ratings Changes

DMRA has been the topic of a number of research reports. Royal Bank Of Canada began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Finally, Wedbush raised their target price on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors have recently bought and sold shares of DMRA. Two Sigma Investments LP bought a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at $76,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth $49,000. Connective Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter valued at about $100,000. Geode Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $266,000. Finally, Remedium Capital Partners LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $2,772,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.